Clients choose us for provider-guided weight loss consultations, personalized metabolic wellness planning, education around GLP-1 and next-generation weight loss research, premium in-lounge and virtual care options, local access across NY, including NYC, Newburgh, Westchester, and the Hudson Valley, and integrated support with IV therapy, peptides, hormone wellness, recovery, and longevity optimization
2.4% placebo (N=1,961) Oral semaglutide 50 mg / phase 3 OASIS-1 showed 15.1% weight loss at 68 weeks CagriSema / semaglutide + cagrilintide
That is one of the reasons Tirzepatide remains such a useful comparator compound in metabolic peptide research
Split dosing reduces the peak by distributing the dose across two smaller injections
The increasing potential and challenges of digital twins